Regulatory

December 10, 2024

Affibody’s Licensee ACELYRIN Announces Top-line Results for Izokibep in Uveitis

Stockholm, Sweden, December 10, 2024. Affibody’s licensee ACELYRIN, INC. today announced that the Phase 2b/3 trial of izokibep in non-infectious, non-anterior uveitis did not meet the primary endpoint. Izokibep...

Read more

News

October 20, 2024

Data demonstrating pre-clinical efficacy and safety of Affibody’s radio-therapeutic anti-HER2 agent ABY-271 presented at EANM annual congress

Affibody AB (“Affibody”) announces presentation of data from IND enabling preclinical studies with the radiotherapeutic agent 177Lu-ABY-271 for treatment of HER2 expressing metastatic disease. The data will be presented...

Read more

News

September 19, 2024

Positive Results from Phase 3 Clinical Trial of Izokibep in Hidradenitis Suppurativa to be Presented at EADV 2024 in Late-Breaking Session

Stockholm, Sweden, September 19, 2024. Affibody today announced that the positive results from a Phase 3 trial of izokibep in hidradenitis suppurativa will be presented at the 2024 European...

Read more

Regulatory

August 13, 2024

Positive Phase 3 Results in Hidradenitis Suppurativa Further Strengthen Competitive Profile of Izokibep

• Phase 3 trial of izokibep in patients with hidradenitis suppurativa met primary endpoint of HiSCR75 at week 12, as well as the key secondary endpoints of HiSCR90 and...

Read more

News

June 5, 2024

Positive 16-week Data From Phase 2b/3 Trial of Izokibep in Psoriatic Arthritis Presented at EULAR 2024 Late Breaking Session

Stockholm, Sweden, June 5, 2024. Affibody today announced that positive 16-week data from a global Phase 2b/3 trial of izokibep in psoriatic arthritis (PsA) will be presented at the...

Read more

Regulatory

May 16, 2024

Report from Annual General Meeting in Affibody Medical AB (publ)

Solna, Sweden, May 16, 2024 – Affibody Medical AB (publ) today held its Annual General Meeting. The following resolutions were adopted. Adoption of the income statement and the balance...

Read more

Regulatory

April 19, 2024

Affibody publishes Annual Report 2023

Stockholm, Sweden, April 19, 2024. Affibody Medical AB (publ) today announced that the Annual Report for 2023 now is available at the company’s website, and as an attachment to...

Read more

News

April 18, 2024

NOTICE OF ANNUAL GENERAL MEETING IN AFFIBODY MEDICAL AB (PUBL)

The shareholders of Affibody Medical AB (publ), corporate identity number 556714-5601 (the “Company” or “Affibody”) are hereby invited to attend the annual general meeting of the shareholders on Thursday...

Read more

Regulatory

March 26, 2024

First gastroesophageal cancer patients enrolled in Phase 2 basket trial using Affibody’s PET imaging agent ABY-025

Solna, Sweden, March 26, 2024. Affibody AB (“Affibody”) today announced that the first patients with gastroesophageal cancer have been dosed in a Phase 2 clinical basket study of the...

Read more